Effect of transcoronary ablation of septal hypertrophy on clinical outcome in hypertrophic obstructive cardiomyopathy associated with atrial fibrillation

Clinical Research in Cardiology

Volumn 95, Issue 5, 2006, Pages 254-260

  Obergassel, L ^a,c   Lawrenz, T ^a   Gietzen, F H ^b   Lieder, F ^a   Leuner, C ^a   Kuhn, H ^a   Stellbrink, C ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Centre of Cardiovascular Medicine   (Germany)

^c OWL University   (Germany)

Author keywords

Atrial fibrillation; Hypertrophic obstructive cardiomyopathy; Transcoronary alcohol ablation of septal hypertrophy

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; VERAPAMIL;

ADULT; AGED; ARTICLE; CATHETER ABLATION; EXERCISE TOLERANCE; FEMALE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART PALPITATION; HEMODYNAMICS; HOLTER MONITORING; HOSPITAL ADMISSION; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT SELECTION; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRE; SINUS RHYTHM; STATISTICAL ANALYSIS; TRANSCORONARY ABLATION OF SEPTAL HYPERTROPHY; TREATMENT OUTCOME;

ATRIAL FIBRILLATION; CARDIOMYOPATHY, HYPERTROPHIC; ETHANOL; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PREVALENCE; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 33646535351     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-006-0372-0     Document Type: Article

References (30)

1. Crijns HJGM, Tjeerdsma G, de Kam PJ, Boomsma F, van Gelder C, van den Berg MP (2000) Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 21:1238-1245
2. Doll N, Fabricius AM, Gummert JF, Krakor R, Hindricks G, Kottkamp H, Mohr FW (2003) Surgical treatment of therapy resistant atrial fibrillation. Z Kardiol 92:712-720
3. Ehrlich JR, Hohnloser SH (2005) Pharmacological cardioversion of atrial fibrillation. Z Kardiol 94:14-22
4. Faber L, Seggewiss H, Gleichmann U (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 98(22):2415-2421
5. Faber L, Seggewiss H, Welge D, Fassbender D, Ziemssen P, Schmidt HK, Gleichmann U, Horstkotte D (2003) Predicting the risk of atrioventricular conduction lesions after percutaneous septal ablation for obstructive hypertrophic cardiomyopathy. Z Kardiol 92:39-47
6. Faber L, Seggewiss H, Gietzen FH, Kuhn H, Boeckstegers P, Neuhaus L, Seipel L, Horstkotte (2005) Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: Follow-up results of the TASH-registry of the German Cardiac Society. Z Kardiol 94:516-523
7. Fananapazir L, Tracy CM, Leon MB, Winkler JB, Cannon RO 3rd, Bonow RO, Maron BJ, Epstein SE (1989) Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation 80:1259-1268
8. Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G (2004) Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 25:1385-1394
9. Gallagher MM, Camm J (1998) Classification of atrial fibrillation. Am J Cardiol 82:18N-28N
10. Gietzen FH, Leuner ChJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C, Kuhn HJ (1999) Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH): Catheter interventional treatment for hypertrophic cardiomyopathy. Eur Heart J 20:1342-1354
11. Gietzen FH, Leuner CJ, Obergassel L, Strunk-Mueller C, Kuhn H (2002) Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York Heart Assocociation functional class III and IVand outflow obstruction only under provocable conditions. Circulation 106(4):454-459
12. Kirchhof P, Engelen M, Franz MR, Ribbing M, Wasmer K, Breithardt G, Haverkamp L, Eckardt (2005) Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation. Basic Res Cardiol 100:112-121
13. Kuhn H, Gietzen FH, Leuner Ch, Schäfers M, Schober O, Strunk-Müller C, Obergassel L, Freick M, Gockel B, Lieder F, Reite-Kreinsen U (2000) Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 89(Suppl 4:IV): 41-54
14. Kuhn H, Seggewiss H, Gietzen FH, Boekstegers P, Neuhaus L, Seipel L (2004) Catheter-based therapy for hypertrophic obstructive cardiomyopathy: First in-hospital outcome analysis of the German TASH Registry. Z Kardiol 93:23-31
15. Kuhn H, Gietzen F, Leuner C, Gerenkamp T (1997) Induction of subaortic septal ischemia to reduce obstruction in hypertrophic obstructive cardiomyopathy: studies to develop a new catheter based concept of treatment. Eur Heart J 18:846-851
16. Kuhn H, Lawrenz T, Lieder F, Gietzen F, Obergassel L, Strunk-Mueller C, Stolle B, Leuner CJ (2004) Alcohol septal ablation in the treatment of hypertrophic obstructive cardiomyopathy: a seven-year experience. In: Maron BJ (ed) Diagnosis and Management of Hypertrophic Cardiomyopathy, 1st edn. Blackwell Futura, Malden, pp 279-296
17. Lawrenz Th, Obergassel L, Lieder F, Leuner Ch, Strunk-Mueller C, Meyer zu Vilsendorf D, Beer G, Kuhn H (2005) Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy. PACE 28:1-6
18. Loogen F, Kuhn H, Gietzen F, Losse B, Schulte HD, Bircks W (1983) Clinical course and prognosis of patients with typical and atypical hypertrophic obstructive and with hypertrophic non-obstructive cardiomyopathy. Eur Heart J 4(Suppl F):145-153
19. López Gil M, Arribas F, Cosio FG (2000) Ventricular fibrillation incuced by rapid atrial rates in patients with hypertrophic cardiomyopathy. Europace 2:327-332
20. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, TenCate FJ, Wigle ED (2003) American college of cardiology/european society of cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 24:1965-1991
21. Obergassel L, Gietzen FH, Strunk-Mueller C, Meyer zu Vilsendorf D, Lawrenz T, Bartelsmeier, Kuhn HJ (2001) Does Transcoronary Ablation of Septal Hypertrophy (TASH) in Hypertrophic Cardiomyopathy (HOCM) Induce an Arrhythmogenic Substrate? Clinical Results and Holter-ECG-Data. PACE 24(4):694
22. Obergassel L, Lawrenz Th, Meyer zu Vilsendorf D, Gietzen FH, Strunk-Mueller C, Kuhn H (2001) His-Bündel-Ablation (HBA) bei hypertrophisch-obstruktiver Kardiomyopathie (HOCM) und tachykardem Vorhofflimmern. Z Kardiol 90(Suppl 5):V/76
23. Obergassel L, Lawrenz T, Gietzen FH, Strunk-Mueller C, Kuhn H (2002) Atrial fibrillation in hypertrophic obstructive cardiomyopathy: prevalence, symptoms and quality of live. Eur H Jour 23(Abstr Suppl):487
24. Olivotto I, Cecchi F, Casey SA, Dolora A, Traverse JH, Maron BJ (2001) Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104:2517-2524
25. Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ (1990) Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 15:1279-1285
26. Siegwart U (1995) Non surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346:211-214
27. Sopher SM, Camm AJ (1996) Atrial fibrillation: maintenance of sinus rhythm versus rate control. Am J Cardiol 77:24A
28. Stellbrink C (2005) Treatment of life-threatening cardiac arrhythmias. Internist 46(3):275-284
29. Ueng KC, Tsai TP, Tsai CF, Wu DJ, Lin CS, Lee SH, Chen SA (2001) Acute and long-term effects of atrioventricular junction ablation and VVIR pacemaker in symptomatic patients with chronic lone atrial fibrillation and normal ventricular response. J Cardiovasc Electrophysiol 12:303-309
30. Wise DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalqist JE, Corley SD (AFFIRM Investigators) (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825-1833